2014 Q4 Form 10-Q Financial Statement
#000114420414068712 Filed on November 14, 2014
Income Statement
| Concept | 2014 Q4 | 2014 Q3 | 2013 Q3 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $100.0K |
| YoY Change | -100.0% | ||
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $1.250M | $770.0K | $860.0K |
| YoY Change | 45.35% | -10.47% | 28.36% |
| % of Gross Profit | |||
| Research & Development | $1.372M | $2.120M | $810.9K |
| YoY Change | 87.73% | 161.45% | 57.94% |
| % of Gross Profit | |||
| Depreciation & Amortization | $40.00K | $60.00K | $70.00K |
| YoY Change | -50.0% | -14.29% | 16.67% |
| % of Gross Profit | |||
| Operating Expenses | $1.372M | $2.120M | $810.9K |
| YoY Change | 87.73% | 161.45% | 57.94% |
| Operating Profit | -$10.75M | -$5.186M | -$1.753M |
| YoY Change | 576.38% | 195.86% | 40.65% |
| Interest Expense | $995.00 | $1.785K | -$31.60K |
| YoY Change | -103.24% | -105.65% | -7.0% |
| % of Operating Profit | |||
| Other Income/Expense, Net | |||
| YoY Change | |||
| Pretax Income | -$10.75M | -$5.180M | -$1.780M |
| YoY Change | 563.58% | 191.01% | -14.83% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$10.75M | -$5.184M | -$1.784M |
| YoY Change | 563.49% | 190.52% | -14.44% |
| Net Earnings / Revenue | -1784.33% | ||
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$15.14M | -$7.507M | -$14.83M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 13.87M shares | 13.85M shares | 231.9M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2014 Q4 | 2014 Q3 | 2013 Q3 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $2.110M | $3.840M | $790.0K |
| YoY Change | -65.52% | 386.08% | -39.69% |
| Cash & Equivalents | $1.737M | $3.837M | $789.2K |
| Short-Term Investments | |||
| Other Short-Term Assets | $60.00K | $160.0K | $1.570M |
| YoY Change | -95.97% | -89.81% | 7.53% |
| Inventory | |||
| Prepaid Expenses | $163.1K | $1.567M | |
| Receivables | $203.9K | $43.13K | |
| Other Receivables | $0.00 | $0.00 | |
| Total Short-Term Assets | $2.370M | $4.043M | $2.356M |
| YoY Change | -68.86% | 71.64% | -15.01% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $260.0K | $262.6K | $4.032K |
| YoY Change | 7303.19% | 6413.72% | -37.88% |
| Goodwill | $13.90M | $13.90M | |
| YoY Change | |||
| Intangibles | $123.5K | $3.450M | |
| YoY Change | -96.42% | -0.77% | |
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $60.00K | $10.00K | $10.00K |
| YoY Change | 500.0% | 0.0% | 0.0% |
| Total Long-Term Assets | $16.18M | $24.10M | $3.459M |
| YoY Change | 363.56% | 596.59% | -0.84% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $2.370M | $4.043M | $2.356M |
| Total Long-Term Assets | $16.18M | $24.10M | $3.459M |
| Total Assets | $18.55M | $28.14M | $5.815M |
| YoY Change | 67.13% | 383.93% | -7.11% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.305M | $610.0K | $1.004M |
| YoY Change | 173.28% | -39.23% | 7.69% |
| Accrued Expenses | $1.094M | $1.070M | $406.8K |
| YoY Change | 77.34% | 163.04% | 33.38% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $2.190M |
| YoY Change | -100.0% | -100.0% | -0.45% |
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $2.549M | $1.690M | $3.598M |
| YoY Change | -22.32% | -53.03% | 4.7% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $99.73K | $100.0K | $99.73K |
| YoY Change | 0.0% | 0.27% | 0.0% |
| Total Long-Term Liabilities | $99.73K | $100.0K | $99.73K |
| YoY Change | 0.0% | 0.27% | 0.0% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.549M | $1.690M | $3.598M |
| Total Long-Term Liabilities | $99.73K | $100.0K | $99.73K |
| Total Liabilities | $6.614M | $5.710M | $3.697M |
| YoY Change | 95.61% | 54.43% | 1.84% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | |||
| YoY Change | |||
| Common Stock | $138.5K | $23.48K | |
| YoY Change | 489.66% | -97.99% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $2.775M | $22.43M | $2.117M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $18.55M | $28.14M | $5.815M |
| YoY Change | 67.1% | 383.89% | -7.11% |
Cashflow Statement
| Concept | 2014 Q4 | 2014 Q3 | 2013 Q3 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$10.75M | -$5.184M | -$1.784M |
| YoY Change | 563.49% | 190.52% | -14.44% |
| Depreciation, Depletion And Amortization | $40.00K | $60.00K | $70.00K |
| YoY Change | -50.0% | -14.29% | 16.67% |
| Cash From Operating Activities | -$1.530M | -$1.939M | -$670.5K |
| YoY Change | 7.75% | 189.26% | 5.34% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$200.0K | $74.33K | $0.00 |
| YoY Change | 81.82% | -100.0% | |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$200.0K | -$334.8K | -$142.9K |
| YoY Change | 81.82% | 134.22% | -2.76% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 0.000 | $0.00 | $290.00 |
| YoY Change | -100.0% | -100.0% | -99.69% |
| NET CHANGE | |||
| Cash From Operating Activities | -1.530M | -$1.939M | -$670.5K |
| Cash From Investing Activities | -200.0K | -$334.8K | -$142.9K |
| Cash From Financing Activities | 0.000 | $0.00 | $290.00 |
| Net Change In Cash | -1.730M | -$2.274M | -$813.1K |
| YoY Change | -132.4% | 179.69% | 17.97% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$1.530M | -$1.939M | -$670.5K |
| Capital Expenditures | -$200.0K | $74.33K | $0.00 |
| Free Cash Flow | -$1.330M | -$2.014M | -$670.5K |
| YoY Change | 1.53% | 200.35% | 5.13% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2014Q3 | svon |
Acquired Research And Development
AcquiredResearchAndDevelopment
|
9800000 | USD |
| CY2014Q3 | us-gaap |
Goodwill
Goodwill
|
13902917 | USD |
| CY2014Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
6111340 | USD |
| CY2014Q2 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
43133 | USD |
| CY2014Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
43133 | USD |
| CY2014Q3 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
163147 | USD |
| CY2014Q3 | us-gaap |
Assets Current
AssetsCurrent
|
4043419 | USD |
| CY2014Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
262633 | USD |
| CY2014Q3 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
123531 | USD |
| CY2014Q2 | svon |
Acquired Research And Development
AcquiredResearchAndDevelopment
|
9800000 | USD |
| CY2014Q2 | us-gaap |
Goodwill
Goodwill
|
13902917 | USD |
| CY2014Q2 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
3920000 | USD |
| CY2014Q3 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
3920000 | USD |
| CY2014Q2 | us-gaap |
Common Stock Value
CommonStockValue
|
138463 | USD |
| CY2014Q3 | us-gaap |
Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
|
93478573 | USD |
| CY2014Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
22430755 | USD |
| CY2014Q2 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
6 | USD |
| CY2014Q3 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
6 | USD |
| CY2014Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
138463 | USD |
| CY2014Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
115770859 | USD |
| CY2014Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
28137671 | USD |
| CY2014Q2 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
115631726 | USD |
| CY2014Q2 | us-gaap |
Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
|
88280266 | USD |
| CY2014Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
27489929 | USD |
| CY2014Q2 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
33334828 | USD |
| CY2013Q3 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
366504 | USD |
| CY2013Q3 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
10239 | USD |
| CY2013Q3 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
142943 | USD |
| CY2013Q3 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | USD |
| CY2014Q2 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2014Q3 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2014Q2 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2014Q3 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | shares |
| CY2014Q2 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2014Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2014Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | shares |
| CY2014Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
500000000 | shares |
| CY2014Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
13846361 | shares |
| CY2014Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
13846361 | shares |
| CY2014Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
13846361 | shares |
| CY2014Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
13846361 | shares |
| CY2013Q3 | svon |
Common Stock To Be Issued Upon Conversion Of Convertible Preferred Stock
CommonStockToBeIssuedUponConversionOfConvertiblePreferredStock
|
193333 | shares |
| CY2014Q3 | svon |
Common Stock To Be Issued Upon Conversion Of Convertible Preferred Stock
CommonStockToBeIssuedUponConversionOfConvertiblePreferredStock
|
290000 | shares |
| CY2013Q3 | svon |
Number Of Diluted Warrants Outstanding
NumberOfDilutedWarrantsOutstanding
|
282866 | shares |
| CY2014Q3 | svon |
Number Of Diluted Warrants Outstanding
NumberOfDilutedWarrantsOutstanding
|
7237774 | shares |
| CY2013Q3 | svon |
Number Of Diluted Options Outstanding
NumberOfDilutedOptionsOutstanding
|
277240 | shares |
| CY2014Q3 | svon |
Number Of Diluted Options Outstanding
NumberOfDilutedOptionsOutstanding
|
970392 | shares |
| CY2013Q3 | svon |
Potential Dilutive Shares Of Common Stock
PotentialDilutiveSharesOfCommonStock
|
753439 | shares |
| CY2014Q3 | svon |
Potential Dilutive Shares Of Common Stock
PotentialDilutiveSharesOfCommonStock
|
8498166 | shares |
| CY2013Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure |
| CY2014Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P0Y | |
| CY2014Q2 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
6111340 | USD |
| CY2014Q3 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
3837139 | USD |
| CY2013Q3 | us-gaap |
Licenses Revenue
LicensesRevenue
|
100000 | USD |
| CY2014Q3 | us-gaap |
Licenses Revenue
LicensesRevenue
|
0 | USD |
| CY2013Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
856631 | USD |
| CY2014Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
774600 | USD |
| CY2013Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
810937 | USD |
| CY2014Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
2120156 | USD |
| CY2013Q3 | us-gaap |
Interest Paid
InterestPaid
|
32197 | USD |
| CY2014Q3 | us-gaap |
Interest Paid
InterestPaid
|
543 | USD |
| CY2013Q3 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
185161 | USD |
| CY2014Q3 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
2290836 | USD |
| CY2013Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
1852729 | USD |
| CY2014Q3 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
5185592 | USD |
| CY2013Q3 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-31604 | USD |
| CY2014Q3 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
1785 | USD |
| CY2013Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-1784333 | USD |
| CY2014Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-5183807 | USD |
| CY2013Q3 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
21623 | USD |
| CY2014Q3 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
14500 | USD |
| CY2013Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-1805956 | USD |
| CY2014Q3 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-5198307 | USD |
| CY2013Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
0 | USD |
| CY2014Q3 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
0 | USD |
| CY2013Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-1805956 | USD |
| CY2014Q3 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-5198307 | USD |
| CY2013Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.78 | |
| CY2014Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.38 | |
| CY2013Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
2307926 | shares |
| CY2014Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
13846361 | shares |
| CY2013Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
74270 | USD |
| CY2014Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
24977 | USD |
| CY2013Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
46780 | shares |
| CY2013Q3 | us-gaap |
Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
|
201154 | USD |
| CY2014Q3 | svon |
Probability To Achieve Employee Target Goals
ProbabilityToAchieveEmployeeTargetGoals
|
0.81 | pure |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | USD |
| CY2014Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y9M18D | |
| CY2014Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
0 | USD |
| CY2014Q3 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P8Y | |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
265582 | shares |
| CY2014Q3 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P45M | |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
979304 | shares |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
0 | shares |
| CY2014Q3 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
0 | shares |
| CY2014Q3 | svon |
Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
|
8912 | shares |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
0 | shares |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
970392 | shares |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
458304 | shares |
| CY2014Q2 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.49 | |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
5.40 | |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
0 | |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
9.52 | |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
16.73 | |
| CY2014Q2 | svon |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit
|
2.65 | |
| CY2014Q2 | svon |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit
|
345.00 | |
| CY2014Q3 | svon |
Share Based Compensation Shares Authorized Under Stock Option Plans Granted Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansGrantedExercisePrice
|
0 | |
| CY2014Q3 | svon |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercised In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisedInPeriodExercisePrice
|
0 | |
| CY2014Q3 | svon |
Share Based Compensation Shares Authorized Under Stock Option Plans Cancelled In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansCancelledInPeriodExercisePrice
|
5.40 | |
| CY2014Q3 | svon |
Share Based Compensation Shares Authorized Under Stock Option Plans Expirations In Period Exercise Price
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExpirationsInPeriodExercisePrice
|
0 | |
| CY2014Q3 | svon |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerLimit
|
2.65 | |
| CY2014Q3 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-288160 | USD |
| CY2014Q3 | svon |
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperLimit
|
345.00 | |
| CY2014Q3 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
|
139133 | USD |
| CY2014Q3 | us-gaap |
Dividends
Dividends
|
-14500 | USD |
| CY2013Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
124466 | USD |
| CY2014Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
139133 | USD |
| CY2013Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
74793 | USD |
| CY2014Q3 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
60146 | USD |
| CY2013Q3 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-352705 | USD |
| CY2014Q3 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-237028 | USD |
| CY2014Q3 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
135677 | USD |
| CY2013Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-670465 | USD |
| CY2014Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-1939397 | USD |
| CY2014Q3 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
260477 | USD |
| CY2014Q3 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
74327 | USD |
| CY2013Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-142943 | USD |
| CY2014Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-334804 | USD |
| CY2013Q3 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
290 | USD |
| CY2014Q3 | us-gaap |
Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
|
0 | USD |
| CY2013Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
290 | USD |
| CY2014Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
0 | USD |
| CY2013Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-813118 | USD |
| CY2014Q3 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-2274201 | USD |
| CY2013Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
1602294 | USD |
| CY2013Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
789176 | USD |
| CY2013Q3 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
73331 | USD |
| CY2014Q3 | us-gaap |
Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
|
0 | USD |
| CY2013Q3 | us-gaap |
Stock Issued1
StockIssued1
|
12623 | USD |
| CY2014Q3 | us-gaap |
Stock Issued1
StockIssued1
|
0 | USD |
| CY2013Q3 | svon |
Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
|
9000 | USD |
| CY2014Q3 | svon |
Preferred Dividends Accrued Not Yet Paid
PreferredDividendsAccruedNotYetPaid
|
14500 | USD |
| CY2014Q3 | dei |
Document Type
DocumentType
|
10-Q | |
| CY2014Q3 | dei |
Amendment Flag
AmendmentFlag
|
false | |
| CY2014Q3 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-09-30 | |
| CY2014Q3 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2015 | |
| CY2014Q3 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
| CY2014Q3 | dei |
Entity Registrant Name
EntityRegistrantName
|
Sevion Therapeutics, Inc. | |
| CY2014Q3 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001035354 | |
| CY2014Q3 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--06-30 | |
| CY2014Q3 | dei |
Entity Filer Category
EntityFilerCategory
|
Smaller Reporting Company | |
| CY2014Q3 | dei |
Trading Symbol
TradingSymbol
|
SVON | |
| CY2014Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
13866627 | shares |
| CY2013Q3 | svon |
Writeoff Of Prepaid Research Supplies
WriteoffOfPrepaidResearchSupplies
|
0 | USD |
| CY2014Q3 | svon |
Writeoff Of Prepaid Research Supplies
WriteoffOfPrepaidResearchSupplies
|
669750 | USD |
| CY2014Q3 | us-gaap |
Basis Of Accounting
BasisOfAccounting
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><b>Note 1 - Basis of Presentation:</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The financial statements included herein have been prepared by Sevion Therapeutics, Inc. (the “Company”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On September 29, 2014, the Company changed its name from Senesco Technologies, Inc. to Sevion Therapeutics, Inc.</div>   <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting solely of those which are of a normal recurring nature, necessary to present fairly its financial position as of September 30, 2014 and the results of its operations for the three months ended September 30, 2014 and cash flows for the three months ended September 30, 2014.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Certain prior year amounts have been reclassified from general and administrative expenses to research and development expenses for consistency with the current period presentation. These reclassifications had no effect on the reported results of operations or cash flows from operations in the Consolidated Condensed Statement of Cash Flows, and had no effect on the previously reported Consolidated Condensed Statement of Operations for any period.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0in; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Interim results are not necessarily indicative of results for the full fiscal year.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | |
| CY2014Q3 | us-gaap |
Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
|
P17Y | |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0 | pure |
| CY2013Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.99 | pure |
| CY2014Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0 | pure |
| CY2013Q3 | svon |
Issuance Of Additional Options
IssuanceOfAdditionalOptions
|
26500 | shares |
| CY2014Q3 | svon |
Options Aggregated During Period
OptionsAggregatedDuringPeriod
|
108650 | USD |
| CY2014Q3 | svon |
Unrecognized Share Based Compensation Expense
UnrecognizedShareBasedCompensationExpense
|
1137000 | USD |
